Intelligent Bio Solutions Inc.

Intelligent Bio Solutions Inc. is a medical technology company focused on delivering intelligent, rapid, and non-invasive testing solutions. Headquartered in New York, New York, the company's mission is to redefine testing by providing pain-free, accessible solutions that enhance the quality of life and drive transformative change through innovation.

The company's flagship product is the Intelligent Fingerprinting Drug Screening System, a portable, three-part solution that utilizes fingerprint sweat analysis to detect recent drug use, including opiates, methamphetamine, cocaine, cannabis, and benzodiazepines. This system offers a hygienic, non-invasive, and rapid on-site screening method, providing results in under ten minutes. Intelligent Bio Solutions also develops a proprietary biosensor platform for detecting biomarkers from non-invasive samples and offers the SmarTest Patch for continuous drug monitoring. Its solutions are employed across various safety-critical industries such as construction, logistics, healthcare, government, drug treatment, manufacturing, engineering, transport, law enforcement, and forensics in over 24 countries.

Led by CEO Harry Simeonidis, appointed in October 2022, Intelligent Bio Solutions is strategically positioned within the global drug screening market, which is projected for significant growth. The company is actively pursuing a planned U.S. market launch in 2025/2026, with its FDA 510(k) clearance process underway, including recent clinical studies and successful penetration testing completed in early 2026. Recent notable developments include strengthening its European intellectual property portfolio with an eighth patent grant in March 2026 and establishing a strategic manufacturing partnership with Syrma Johari MedTech in December 2025 to scale production and improve margins.